Compile Data Set for Download or QSAR
Report error Found 8 Enz. Inhib. hit(s) with all data for entry = 7616
TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM50322535(3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-meth...)
Affinity DataIC50: 1nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM206084(US9255107, 3)
Affinity DataIC50: 2.12nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM206085(US9255107, 5)
Affinity DataIC50: 2.28nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM206087(US9255107, 9)
Affinity DataIC50: 6.45nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM206089(US9255107, 19)
Affinity DataIC50: 6.81nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM206086(US9255107, 6)
Affinity DataIC50: 39.4nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM206088(US9255107, 18)
Affinity DataIC50: 57.9nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1 [T315I](Human)
Nanjing Sanhome Pharmaceutical

US Patent
LigandPNGBDBM13530(cid_5291 | STI571 | N-(4-methyl-3-{[4-(pyridin-3-y...)
Affinity DataIC50: 1.00E+3nMT: 2°CAssay Description:Serially diluting the compound of the present invention from 1 uM initial concentration in three-fold fashion and formulating 10 concentrations (50.8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details
US Patent